Treatment that combines chemotherapy with radiotherapy.
Combined chemotherapy and radiotherapy given to augment some other form of treatment such as surgery. It is commonly used in the therapy of cancer.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Tumors or cancer of the ESOPHAGUS.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Tumors or cancer of the RECTUM.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Excision of part (partial) or all (total) of the esophagus. (Dorland, 28th ed)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A malignant epithelial tumor with a glandular organization.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.
Tumors or cancer of the NASOPHARYNX.
Antimetabolites that are useful in cancer chemotherapy.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the HYPOPHARYNX.
Tumors or cancer of the LUNG.
Techniques, procedures, and therapies carried out on diseased organs in such a way to avoid complete removal of the organ and preserve the remaining organ function.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
An organoplatinum compound that possesses antineoplastic activity.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.
Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.
Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.
Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)
Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Tumors or cancer of the OROPHARYNX.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Surgery performed on the digestive system or its parts.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Organic compounds which contain platinum as an integral part of the molecule.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice.
Therapeutic act or process that initiates a response to a complete or partial remission level.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
Tumors or cancer of the UTERINE CERVIX.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tumors or cancer of the ANAL CANAL.
Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed)
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
Antagonist of urate oxidase.
CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.
INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
A general concept for tumors or cancer of any part of the EAR; the NOSE; the THROAT; and the PHARYNX. It is used when there is no specific heading.
Elements of limited time intervals, contributing to particular results or situations.
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Total or partial excision of the larynx.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Tumors or cancer of the pelvic region.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A tubular organ of VOICE production. It is located in the anterior neck, superior to the TRACHEA and inferior to the tongue and HYOID BONE.
Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis.
The excision of lung tissue including partial or total lung lobectomy.
Tumors or cancer of the STOMACH.
Pathological processes that affect voice production, usually involving VOCAL CORDS and the LARYNGEAL MUCOSA. Voice disorders can be caused by organic (anatomical), or functional (emotional or psychological) factors leading to DYSPHONIA; APHONIA; and defects in VOICE QUALITY, loudness, and pitch.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Tumors or cancer of the human BREAST.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Transplantation of an individual's own tissue from one site to another site.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Tumors or cancer of the PHARYNX.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Used for excision of the urinary bladder.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Spasmodic contraction of the masseter muscle resulting in forceful jaw closure. This may be seen with a variety of diseases, including TETANUS, as a complication of radiation therapy, trauma, or in association with neoplastic conditions.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
The vocal apparatus of the larynx, situated in the middle section of the larynx. Glottis consists of the VOCAL FOLDS and an opening (rima glottidis) between the folds.
Tumors or cancer of the NOSE.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
The return of a sign, symptom, or disease after a remission.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
The use of combination of imaging techniques or platforms (e.g., MRI SCAN and PET SCAN) encompassing aspects of anatomical, functional, or molecular imaging methods.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
The period following a surgical operation.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Surgical removal of a part of the pharynx. (Dorland, 28th ed)
The study of chance processes or the relative frequency characterizing a chance process.
The act of taking solids and liquids into the GASTROINTESTINAL TRACT through the mouth and throat.
The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Delivery of medications through the nasal mucosa.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Antibodies produced by a single clone of cells.
Dissection in the neck to remove all disease tissues including cervical LYMPH NODES and to leave an adequate margin of normal tissue. This type of surgery is usually used in tumors or cervical metastases in the head and neck. The prototype of neck dissection is the radical neck dissection described by Crile in 1906.
Tumors or cancer of the URINARY BLADDER.
A subspecialty of internal medicine concerned with the study of neoplasms.
Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A subspecialty of medical oncology and radiology concerned with the radiotherapy of cancer.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
ARTHRITIS that is induced in experimental animals. Immunological methods and infectious agents can be used to develop experimental arthritis models. These methods include injections of stimulators of the immune response, such as an adjuvant (ADJUVANTS, IMMUNOLOGIC) or COLLAGEN.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A decrease in the number of NEUTROPHILS found in the blood.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Tumors or cancer of the MOUTH.
Surgical incision into the chest wall.
Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The act of dilating.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.
A subnormal level of BLOOD PLATELETS.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.
Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.
The period before a surgical operation.
An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. (1/158)

 (+info)

Long-term toxic effects of adjuvant chemotherapy in breast cancer. (2/158)

 (+info)

Elevation in exhaled nitric oxide predicts for radiation pneumonitis. (3/158)

 (+info)

Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement? (4/158)

 (+info)

Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. (5/158)

 (+info)

Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. (6/158)

Strong evidence exists for the use of adjuvant chemotherapy following surgical resection in pancreatic cancer, whereas the role of adjuvant chemoradiotherapy remains controversial. The optimal time to initiate adjuvant therapy has yet to be elucidated, but is usually started 2-10 weeks following resection. First line adjuvant chemotherapy is gemcitabine, as this drug has demonstrated the better efficacy in studies. Other chemotherapeutic agents and gemcitabine in combination with biologic agents are under investigation. Furthermore, predicting response to gemcitabine based chemotherapy and other adjuvant therapies will be invaluable in guiding the practitioner to choose the most appropriate adjuvant treatment. Once adjuvant therapy has been started, accurately quantifying response to therapy is also important. The adjuvant regimen may be appropriately modified if response is inadequate. This review is an update from the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding recent developments in the adjuvant treatment of pancreatic cancer with regards to choice of adjuvant regimen, timing of adjuvant therapy, predicting response to therapy and measuring response to adjuvant therapy. We will present the findings from Abstracts #4039, #4042, #e14519, #4118, and #4024. In conclusion, multiple adjuvant therapeutic regimens are associated with incremental improvements in the management of pancreatic cancer. The timing of initiation of adjuvant therapy appears to be important in outcomes. Research is ongoing into markers that can predict response to adjuvant therapy.  (+info)

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. (7/158)

 (+info)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). (8/158)

 (+info)

Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy system.
Muscle degeneration has been consistently identified as an independent risk factor for high mortality in both aging populations and individuals suffering from neuromuscular pathology or injury. While there is much extant literature on its quantification and correlation to comorbidities, a quantitative gold standard for analyses in this regard remains undefined. Herein, we hypothesize that rigorously quantifying entire radiodensitometric distributions elicits more muscle quality information than average values reported in extant methods. This study reports the development and utility of a nonlinear trimodal regression analysis method utilized on radiodensitometric distributions of upper leg muscles from CT scans of a healthy young adult, a healthy elderly subject, and a spinal cord injury patient. The method was then employed with a THA cohort to assess pre- and postsurgical differences in their healthy and operative legs. Results from the initial representative models elicited high degrees of
However, as previously mentioned, it is the incongruent conditions that probe the statistical inference rules that the nervous system must use in resolving potential conflicts in sensory cues. In incongruent conditions, there are often considerable deviations from the veridical response in one or more of the modalities. In other words, the information in the task-irrelevant one or two modalities affects the response distribution in the task-relevant modality. However, not all differences between two response distributions necessarily reflect meaningful interactions between modalities, as they may be due to sampling error. For example, the change in the visual response between unimodal condition [ V = 1, A = 0, T = 0] and bimodal condition [ V = 1, A = 2, T = 0] may be either statistically insignificant or could correspond to a statistically significant modulation of visual perception by sound. Therefore, to find which of the changes between two conditions correspond to a statistically ...
During the time after Simones diagnosis, everything felt heightened - including my gratitude. Simone was readmitted to the hospital on a Wednesday - the day when she thought her chemotherapy treatment would begin, but which turned out to be the day she learned she was beyond treatment. I planned once again to spend the nights…
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide. Surgery alone cannot obtain satisfactory effects in patients with EC. Neoadjuvant chemoradiotherapy has been a hotspot for EC treatment research. Several related randomized controlled trials (RCTs) have been published, but opinions vary among clinicians as to the therapeutic effect of the new method. It remains uncertain whether patients with resectable EC can benefit from neoadjuvant chemoradiotherapy.. A research article to be published on December 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team from China selected eleven randomized controlled trials (RCTs) including 1308 patients. The reuslts showed neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone. Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvant chemoradiotherapy.. Their meta-analysis suggest that patients ...
To evaluate the benefit of adjuvant treatments, such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB) cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n = 39, 25.8%), and the remaining 53 (35.1%) did not (No-AT). The clinicopathological factors, patterns of failure, locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS) and overall survival (OS) were compared among the three groups according to tumor stage. In patients with T2-3N0M0 stage disease, the incidences of locoregional recurrence and distant recurrence and 5-year LRFS, RFS and OS rates were not significantly different among the No-AT, CTx, and CRT groups (p | 0.05 each). In those with T2-3N1-2M0 stage disease, the incidences of locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively) and distant recurrence (42.8%, 73.9% and 66.7%, respectively) in the CRT group were
The likelihood of a tumor recurrence in patients with T3-4N0-1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens are seen in only a minority (28-38%) of patients following chemoradiotherapy, we designed the INCREASE trial (EudraCT-Number: 2019-003454-83; Netherlands Trial Register number: NL8435) to assess if pCR rates could be further improved by adding short course immunotherapy to induction chemoradiotherapy. Translational studies will correlate changes in loco-regional and systemic immune status with patterns of recurrence. This single-arm, prospective phase II trial will enroll 29 patients with either resectable, or borderline resectable, T3-4N0-1 NSCLC. The protocol was approved by the institutional ethics committee. Study enrollment commenced in February 2020. On day 1 of guideline-recommended concurrent chemoradiotherapy (CRT), ipilimumab (IPI, 1 mg/kg IV) and nivolumab
Oesophageal adenocarcinoma (OAC) is the sixth most common cause of cancer deaths worldwide, and the 5-year survival rate for patients diagnosed with the disease is approximately 17%. The standard of care for locally advanced disease is neoadjuvant chemotherapy or, more commonly, combined neoadjuvant chemoradiation therapy (neo-CRT) prior to surgery. Unfortunately, ~60-70% of patients will fail to respond to neo-CRT. Therefore, the identification of biomarkers indicative of patient response to treatment has significant clinical implications in the stratification of patient treatment. Furthermore, understanding the molecular mechanisms underpinning tumour response and resistance to neo-CRT will contribute towards the identification of novel therapeutic targets for enhancing OAC sensitivity to CRT. MicroRNAs (miRNA/miR) function to regulate gene and protein expression and play a causal role in cancer development and progression. MiRNAs have also been identified as modulators of key cellular ...
BackgroundTo evaluate the value of pretreatment inflammatory-nutritional biomarkers in predicting responses to neoadjuvant chemoradiotherapy (nCRT) and survival in patients with locally advanced rectal cancer (LARC).MethodsPatients with LARC who underwent nCRT and subsequent surgery between October 2012 and December 2019 were considered for inclusion. Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and prognostic nutritional index (PNI) were calculated from according to routine laboratory data within 1 week prior to nCRT. The correlations between baseline inflammatory-nutritional biomarkers and responses were analyzed using Chi-square test or Fishers exact test, and multivariate logistic regression analysis was performed to identify the independent predictors of pathological responses to nCRT. Univariate and multivariate Cox proportional hazard models were used to assess the correlations of predictors with disease-free survival (DFS) and
In this segment, Tanios Bekaii-Saab, MD, FACP; Johanna C. Bendell, MD; Ramesh K. Ramanathan, MD; and Thomas Seufferlein, MD, review their protocols for treating borderline resectable pancreas cancer and considerations in making decisions about the appropriateness for recommending surgery after chemotherapy.
A B S T R AC T BACKGROUND The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well
Noordman, B.J.; Spaander, M.C.W.; Valkema, R.; Wijnhoven, B.P.; Berge Henegouwen, M.I. van; Shapiro, J.; Siersema, P.D.; Janssen, M.J.R.; Post, R.S. van der; Radema, S.A.; Rosman, C. ; Rütten, H.; Lanschot, J.J. van; Steyerberg, E.W. ...
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
NewLink Genetics (NASDAQ: NLNK) announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable ...
Findings from a recent study demonstrate that the PD-L1 inhibitor durvalumab demonstrated statistically significant and clinically meaningful improvement in
Neoadjuvant radiochemotherapy has been proven superior to adjuvant treatment in reducing the rate of local recurrence without impairing cancer related survival or the incidence of distant metastases in standard protocols of neoadjuvant radiochemotherapy. The present study aimed at addressing the effects of an intensified neoadjuvant radiochemotherapy on long term cancer related and disease free survival. A total of 387 patients underwent oncologic resection for rectal cancer in our institution between January 2000 and December 2009. There were 106 patients (27.4%) who received an intensified radiochemotherapy protocol completely and without excluding criteria (study group). A matched pair analysis was performed by comparing the study group with patients undergoing primary surgery and postoperative radiochemotherapy, if necessary and possible (control group). Matching was carried out in descending order for UICC stage, R-status, tumor height, T-, N-, V-, L-, M- and G-category of the TNM-system according
An analysis in the Dutch Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) reported by Noordman et al in the Journal of Clinical Oncology showed no adverse effect of neoadjuvant chemoradiotherapy vs surgery alone on postsurgery health-related quality of life in patients with esophageal or esophagogastric junction cancer.. Study Details. The CROSS study showed significant improvement in overall survival with neoadjuvant chemoradiotherapy (carboplatin plus paclitaxel with concurrent 41.4-Gy radiotherapy) vs surgery alone. In the current analysis, health-related quality of life was assessed by the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and -Oesophageal Cancer Module (QLQ-OES24) questionnaires prior to treatment and at 3, 6, 9, and 12 months after surgery; the neoadjuvant therapy group also received preoperative questionnaires. QLQ-C30 physical functioning and QLQ-OES24 eating problems were predefined primary ...
As a charity, Action Radiotherapy is entirely reliant on donations to support our work. We are extremely grateful to Varian for providing a charitable donation to support our radiotherapy news service. If you would like to receive a daily email with the latest radiotherapy news, please sign up here. ...
Rectal cancer is a frequent but curable malignancy in the Western world. The golden standard in treating these patients consists of neoadjuvant chemoradiotherapy (CRT) followed by extensive surgery regardless of tumor response. The main question is whether extensive surgery can be avoided holding in mind that already a significant amount of patients reach a pathological complete response after radiochemotherapy. The goal of this study is dual. First of all, the investigators want to investigate the value of DW-MRI and 18FDG-PET in the assessment of response after neoadjuvant CRT in 100 patients with rectal cancer, to select those patients eligible for less invasive surgery. In the same patient group, the investigators will examine the biomarker potential of molecular characteristics of the tumor in blood and tissue. Using both molecular and radiological findings, the investigators want to predict pathological response after chemoradiotherapy and to select patients who may benefit from treatment ...
Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters Academic Article ...
Locally advanced rectal cancer is regularly treated with trimodality therapy consisting of neoadjuvant chemoradiation, surgery and adjuvant chemotherapy. There is a need for biomarkers to assess treatment response, and aid in stratification of patient risk to adapt and personalise components of the therapy. Currently, pathological stage and tumour regression grade are used to assess response. Experimental markers include proteins involved in cell proliferation, apoptosis, angiogenesis, the epithelial to mesenchymal transition and microsatellite instability. As yet, no single marker is sufficiently robust to have clinical utility. Microarrays that screen a tumour for multiple promising candidate markers, gene expression and microRNA profiling will likely have higher yield and it is expected that a combination or panel of markers would prove most useful. Moving forward, utilising serial samples of circulating tumour cells or circulating nucleic acids can potentially allow us to demonstrate tumour
TY - JOUR. T1 - Current Concepts on the Distal Margin of Resection of Rectal Cancer Tumors after Neoadjuvant Chemoradiation. AU - Imran, Jonathan. AU - Yao, Jie J.. AU - Madni, Tarik. AU - Huerta, Sergio. PY - 2017/1/23. Y1 - 2017/1/23. N2 - Purpose of Review: The following review addresses concepts regarding the appropriate distal margin of resection for adenocarcinoma of the rectum in the era of preoperative chemoradiation. Recent Findings: The management of adenocarcinoma of the rectum continues to improve in all aspects of its tri-modality treatment (preoperative chemoradiation, surgery, and adjuvant therapy). The multidisciplinary approach to the management of this disease continues to evolve with a goal to provide better oncologic outcomes with less morbidity in patients affected by this disease. For locoregionally advanced disease, total mesorectal excision continues to be the standard of care for an intended cure for this cohort of patients. As we understand more regarding the oncologic ...
Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumours with dismal prognosis. Although curative resection with adjuvant chemoradiotherapy is the most effective treatment, the
Inclusion Criteria: - Histologically confirmed diagnosis of supratentorial WHO Grade III or IV Glioma (High Grade Glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression. - 18 years of age or older - Karnofsky Performance Status 70-100; - MRI demonstration of a stereotactically accessible enhancing or predominantly non- enhancing mass that does not require resection to relieve clinically significant mass effect; - Participant understands the procedures and agrees to comply with the study requirements by providing written informed consent - Adequate organ function as indicated in protocol Exclusion Criteria: - Participant is mentally or legally incapacitated at the time of the study; - Known HIV(+) or has been diagnosed with AIDS - Participation in another investigational drug study in the prior 4 weeks - ...
Rectal cancer is a frequent but curable malignancy in the Western world. The golden standard in treating these patients consists of neoadjuvant chemorad
Abstract: Objective: To evaluate the clinical relevance of preoperative airway colonisation in patients undergoing oesophagectomy for cancer after a neoadjuvant chemoradiotherapy. Methods: From 1998 to 2005, 117 patients received neoadjuvant chemoradiotherapy for advanced stage oesophageal cancer. Among them, 45 non-randomised patients underwent a bronchoscopic bronchoalveolar lavage (BAL group) prior to surgery to assess airways colonisation. The remaining patients (n =72) constituted the control group. The two groups were similar with respect to various clinical or pathological characteristics. Results: Thirteen of the 45 BAL patients (28%) had a preoperative bronchial colonisation by either potentially pathogenic micro-organisms (PPMs) (n =7, 16%) or non-potentially pathogenic micro-organisms (n =6, 13%). Cytomegalovirus (CMV) was cultured from BAL in four patients. Pre-emptive therapy was administrated in seven patients: four antiviral and three antibiotic prophylaxes. Postoperatively, 14 ...
Offline two-dimensional chromatography is a common means to achieve deep proteome coverage. To reduce sample complexity and dynamic range and to utilize mass spectrometer (MS) time efficiently, high chromatographic resolution of and good orthogonality between the two dimensions is needed. Ion exchange and high pH reversed phase chromatography are often used for this purpose. However, the former requires desalting to be MS-compatible and the latter requires fraction pooling to create orthogonality. Here, we report an alternative first-dimension separation technique using a commercial trimodal phase incorporating polar embedded reversed phase, weak anion exchange and strong cation exchange material. The column is capable of retaining polar and nonpolar peptides alike without noticeable breakthrough. It allows separating ordinary and TMT-labelled peptides under mild acidic conditions using an acetonitrile gradient. The direct MS compatibility of solvents and good orthogonality to online coupled C18 ...
Offline two-dimensional chromatography is a common means to achieve deep proteome coverage. To reduce sample complexity and dynamic range and to utilize mass spectrometer (MS) time efficiently, high chromatographic resolution of and good orthogonality between the two dimensions is needed. Ion exchange and high pH reversed phase chromatography are often used for this purpose. However, the former requires desalting to be MS-compatible and the latter requires fraction pooling to create orthogonality. Here, we report an alternative first-dimension separation technique using a commercial trimodal phase incorporating polar embedded reversed phase, weak anion exchange and strong cation exchange material. The column is capable of retaining polar and nonpolar peptides alike without noticeable breakthrough. It allows separating ordinary and TMT-labelled peptides under mild acidic conditions using an acetonitrile gradient. The direct MS compatibility of solvents and good orthogonality to online coupled C18 ...
TY - JOUR. T1 - A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. AU - Nikas, Jason B.. AU - Lee, Janet T.. AU - Maring, Elizabeth D.. AU - Washechek-Aletto, Jill. AU - Felmlee-Devine, Donna. AU - Johnson, Ruth A.. AU - Smyrk, Thomas C.. AU - Tawadros, Patrick S.. AU - Boardman, Lisa A.. AU - Steer, Clifford J. PY - 2015/1/1. Y1 - 2015/1/1. N2 - An important determinant of the pathogenesis and prognosis of various diseases is inherited genetic variation. Single-nucleotide polymorphisms (SNPs), variations at a single base position, have been identified in both protein-coding and noncoding DNA sequences, but the vast majority of millions of those variants are far from being functionally understood. Here we show that a common variant in the gene MTHFR [rs1801133 (C,T)] not only influences response to neoadjuvant chemoradiotherapy in patients with rectal cancer, but it also influences recurrence of the disease itself. More specifically, patients with ...
This trial will assess the efficacy and tolerability of neoadjuvant chemoradiotherapy with bevacizumab + oxaliplatin + fluorouracil in patients with locall
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in loc
Patients with rectal cancer reported aerobic exercise during neoadjuvant chemoradiotherapy to be more enjoyable and less difficult.
Increasing the Rates of Complete Response to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer: Results of a Prospective Study Using Additional Chemotherap
Admixture analysis of age at onset (AAO) has helped delineating the clinical profile of early onset (EO) bipolar disorder (BD). However, there is scarce evidence comparing the distributional properties of AAO as well as the clinical features of EO BD type 1 (BD1) with EO BD type 2 (BD2). To this end, we studied 515 BD patients (224 BD1, 279 BD2, and 12 BD not otherwise specified [NOS]) diagnosed according to DSM-IV-TR criteria. AAO was defined as the first reliably diagnosed hypo/manic or depressive episode according to diagnostic criteria. We used normal distribution mixture analysis to identify subgroups of patients according to AAO. Models were chosen according to the Schwarzs Bayesian information criteria (BIC). Clinical correlates of EO were analysed using univariate tests and multivariate logistic regression models. A two normal components model best fitted the observed distribution of AAO in BD1 (BIC = −1599.3), BD2 (BIC = −2158.4), and in the whole sample (BIC = −3854.9). A higher number
The preparation of a branched, radial block copolymer having improved falling weight impact properties, and having trimodal distribution of molecular structure in the arms of the block copolymer is described.
TY - JOUR. T1 - Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer. T2 - A meta-analytical evaluation of prospective studies. AU - Festa, Virginia. AU - Andriulli, Angelo. AU - Valvano, Maria Rosaria. AU - Uomo, Generoso. AU - Perri, Francesco. AU - Andriulli, Nicola. AU - Corrao, Salvatore. AU - Koch, Maurizio. PY - 2013. Y1 - 2013. N2 - Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therapy remains to be defined. Objective We did a systematic search of the literature on this topic. Methods Prospective studies where chemotherapy with or without radiotherapy was given before surgery to patients with borderline resectable cancer, were analyzed by a metaanalytical approach. Main outcome measures Primary outcome was surgical exploration and resection rates; tumor response, therapy-induced toxicity, and survival were secondary outcomes. Data were expressed as weighted pooled proportions with 95% confidence intervals ...
Dr. Rebeccah Baucom of Vanderbilt University in Nashville, Tennessee and colleagues presented the results of the study June 11 at the 2017 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Seattle, Washington.. Patients who have rectal cancer with clinical nodal disease, high-grade tumors, or tumors with perineural or lymphovascular invasion should undergo total mesorectal excison regardless of their tumor response to neoadjuvant radiation, said senior author Dr. Alexander T. Hawkins of Vanderbilt University.. The findings showed that more aggressive tumors, based on histology and stage, do not respond as well to neoadjuvant chemoradiation therapy, he told Reuters Health by phone.. In a relatively new treatment modality for patients with rectal cancer called watch and wait, patients undergo neoadjuvant chemoradiation therapy, it looks like their tumor goes away, and they can be observed rather than undergo surgery, Dr. Hawkins explained. Our findings are very ...
Background: The accuracy of restaging in patients with stage IIIa non-small cell lung cancer after neoadjuvant chemoradiotherapy is unknown. Methods: A prospective trial of patients with biopsy-proven N2 disease who underwent initial clinical staging with mediastinoscopy, integrated positron emission tomography/computed tomography (PET/CT), and CT. Patients then were clinically restaged by the same imaging techniques 4 to 12 weeks after their induction chemoradiation therapy and then underwent definitive pathologic staging. Results: Ninety-three patients had their lymph nodes pathologically restaged. Repeat PET/CT after neoadjuvant therapy missed residual N2 disease in 13/65 (20%) patients and falsely suggested it in 7 of 28 (25%). It was more accurate than repeat CT for restaging at all pathologic stages (stage 0, 92% vs 39%, P = .03; and stage I 89% vs 36%, P = .04). When the maximum standardized uptake value of the primary tumor is decreased by 75% or more, it is highly likely (likelihood ...
TY - JOUR. T1 - Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. AU - Cheng, Tsung Yen. AU - Sheth, Ketan. AU - White, Rebekah R.. AU - Ueno, Tomio. AU - Hung, Cheng Fang. AU - Clary, Bryan M.. AU - Pappas, Theodore N.. AU - Tyler, Douglas S.. PY - 2006/1/1. Y1 - 2006/1/1. N2 - Background: Neoadjuvant chemoradiotherapy (neo-CRT) is being used with increasing frequency for periampullary tumors, but how it alters the complication rate of pancreaticoduodenectomy (PD) is unclear. Methods: A retrospective analysis was conducted of 79 patients with periampullary malignancies who received 5-fluorouracil-based neo-CRT followed by PD. Results: There was no difference in mortality between PD after neo-CRT (3.8%) and conventional PD for either malignant (4.5%) or benign (2.2%) disease. Focusing only on patients with malignancy, the neo-CRT group had a significantly lower pancreatic leak rate than the conventional group (10% vs. 43%; P , .001). ...
Background In the United Kingdom, patients with locally advanced rectal cancer routinely receive neoadjuvant chemoradiotherapy. capacity muscle mitochondrial function raises the possibility that muscle mitochondrial mechanisms, no doubt multifactorial, may be important in deterioration of physical fitness following neoadjuvant chemoradiotherapy. This may have implications for targeted interventions to improve physical fitness pre-surgery. Trial Registration Clinicaltrials.gov registration type:clinical-trial,attrs:text:NCT01859442″,term_id:NCT01859442″NCT01859442 Introduction In the UK colorectal cancer is the third commonest cause of cancer death [1], [2]. In 2013, 9000 patients were diagnosed with rectal cancer (35% aged >75 y), of whom 4600 underwent major resection with a 90-day elective postoperative mortality of 2.5% [3]. 25% are locally advanced (Tumour, Node, Metastasis (TNM) stage - T3/T4N+) cancers (i.e. resection margin threatened) considered for neoadjuvant ...
Background Patients with locally advanced rectal cancer receive neoadjuvant chemoradiation therapy (CRT) and subsequent surgery. While 10-25% of patients have complete response to CRT, the remaining patients undergo extensive tumor excision resulting in significant quality of life issues. Response to CRT is an independent predictor of overall survival highlighting the importance of improving CRT response rates. Several tumor intrinsic factors govern responses to CRT including specific gene expression programs. Emerging evidence suggests that microRNAs (miRs) modulate gene expression programs in response to radiation and have been implicated in several pathological processes associated with colorectal cancer progression. In this context, we hypothesized that differential expression of miRs regulates colorectal cancer radiation sensitivity and can be used as a biomarker to predict radiation efficacy.. Methods To investigate the differences in miR profiles between rectal cancer patients that had ...
[Over the last several decades, local control (LC) for rectal cancer has markedly improved because of advances in surgical technique and the adoption of adjuvant or neoadjuvant chemoradiotherapy (CRT). Total mesorectal excision (TME) during surgical resection of localized rectal cancer, which involves removal of the entire circumferential perirectal tissue envelope, decreases rates of both involved surgical margins and local recurrences. Similarly, for patients with locally advanced rectal cancer (LARC), including T3 and T4 tumors and lymph node-positive disease, adjuvant and more preferably neoadjuvant CRT has exhibited the ability to both improve disease-free survival (DFS) and LC. Some patients undergoing neoadjuvant CRT achieve a complete pathologic response (pCR) to CRT and the oncologic outcomes are particularly favourable in this group. In contrast to improved local control, patients overall survival rates are in need of improvement, and the major factor limiting the outcome is the appearance of
BACKGROUND: There are no reports available on the long-term outcome of patients with the liver first approach. OBJECTIVES: The aim of this study was to present the long-term results of the liver first approach in our center. DESIGN: This study is a retrospective analysis. SETTING: This study was conducted at a tertiary referral center. PATIENTS: Patients from May 2003 to March 2009 were included. INTERVENTIONS: Patients with locally advanced rectal cancer and synchronous liver metastases were first treated for their liver metastases. If the treatment was successful, patients underwent neoadjuvant chemoradiotherapy and surgery for the rectal cancer. If metastases could not be resected, resection of the rectal primary was not routinely performed. MAIN OUTCOME MEASURES: The primary outcome measured was long-term results of the liver first approach. RESULTS: Of the 42 patients included (median age, 61 years), all but one (98%) started with neoadjuvant chemotherapy. In total, 31 (74%) patients ...
Introduction: Fluorouracil (5-FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5-FU thymidylate synthase (TS) is a promising biomarker in rectal[for full text, please go to the a.m. URL ...
ZnO-containing MFI zeolite catalysts with bimodal and trimodal hierarchical pore structures were prepared, characterized and studied for the conversion of methanol to aromatics. Treatments of H-ZSM-5 with NH4F and NaOH generated bigger micropores with a mean size of around 0.8 nm and mesopores with mean size
Rectal cancer management is becoming increasingly complex. There is increasing recognition of the potential to avoid routine chemoradiotherapy, as excellent results can be achieved with a more selective approach.
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1-2 N1-2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma.. Study Details. The study involved 1,044 patients from the National Cancer Database who were newly diagnosed between 2010 and 2012. Among them, 460 patients (44.1%) received upfront surgery, and 584 patients (55.9%) received chemoradiotherapy. Median age was 59 years (range, 25-90 years), and 77.8% were male. Adjuvant chemoradiotherapy was received by 59% of surgical patients.. Survival Outcomes. Median follow-up was 30 months. Overall, 3-year overall survival was 81.4% in the surgery group vs 79.2% in the chemoradiotherapy group (P = .65). On multivariable analysis, the adjusted hazard ratio for death for surgery vs chemoradiotherapy was 1.01 (P = .93). In a propensity score-matched cohort of 822 patients, the hazard ...
The purpose of the present study was to investigate risk factors associated with local recurrence in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy in combination with total mesorectal excision (TME). Rectal cancer patients who were treated with neoadjuvant chemoradiation with TME were studied. We compared 26 patients who developed local recurrence with 119 recurrence-free patients during the follow-up period. The median follow-up period was 52 months (range: 14â€131 months). Based on the use of univariate and multivariate analyses, circumferential margin involvement ( p = 0.02), the presence of lymphovascular or perineural invasion ( p = 0.02), and positive nodal disease ( p = 0.03) were contributing factors for local recurrence. The local recurrence rate was different between ypN(+) patients and ypN(â€) patients with more than 12 nodes retrieved ( p = 0.01). There was no difference in local recurrence rates between ypN(+) patients and ...
microRNAs (miRNAs) are small non-coding RNAs with important post-transcriptional regulatory functions. miRNA-21 (miR-21) is upregulated and miR-143 and miR-145 are downregulated in colorectal carcinoma. The aim of our study was to determine if these miRNAs change their expression levels in response to neoadjuvant chemoradiotherapy in advanced rectal cancer. Forty patients with advanced rectal cancer (clinical uT3/T4 Nx) were included. All patients underwent neoadjuvant chemoradiotherapy and surgical resection. Expression of miR-21, -143 and -145 was examined in macrodissected tumor tissue before and after chemoradiotherapy and normal rectal tissue from the resection specimen. RNA was extracted from formalin-fixed and paraffin-embedded tissue by TRIzol method, polyadenylated, reverse transcribed and analyzed by real-time PCR. Therapy response was assessed according to pathological tumor regression. miR-21 was more highly expressed in tumor tissue than in non-tumorous tissue. However, there was a ...
OBJECTIVES: We aimed to examine the association between total number of resected nodes and survival in patients after esophagectomy with and without nCRT. BACKGROUND: Most studies concerning the potentially positive effect of extended lymphadenectomy on survival have been performed in patients who underwent surgery alone. As nCRT is known to frequently sterilize regional nodes, it is unclear whether extended lymphadenectomy after nCRT is still useful. METHODS: Patients from the randomized CROSS-trial who completed the entire protocol (ie, surgery alone or chemoradiotherapy + surgery) were included. With Cox regression models, we compared the impact of number of resected nodes as well as resected positive nodes on survival in both groups. RESULTS: One hundred sixty-one patients underwent surgery alone, and 159 patients received multimodality treatment. The median (interquartile range) number of resected nodes was 18 (12-27) and 14 (9-21), with 2 (1-6) and 0 (0-1) resected positive nodes, ...
We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC). This retrospective study investigated the clinicopathological features and | 5-year survival of patients with T3/T4 PDAC who underwent NACRT at our institute between 2003 and 2012. Seventeen resectable and eight borderline resectable patients were included. The protocol treatment completion and resection rates were 92.0% and 68.0%, respectively. Two patients failed to complete chemotherapy owing to cholangitis or anorexia. Common grade 3 toxicities included anorexia (12%), neutropenia (4%), thrombocytopenia (4%), anemia (4%), and leukopenia (12%). Pathologically negative margins were achieved in 94.1% of patients who underwent pancreatectomy. Pathological response according to Evans classification was grade IIA in 10 patients (58.8%), IIB in 5 patients (29.4%), and IV in 2 patients (11.8%). Postoperative
The researchers identified 6 eligible randomized controlled trials. The team found that chemoradiotherapy plus surgery, compared with surgery alone, significantly reduced the 3 year mortality rate (odds ratio 0.53). They also found that preoperative chemoradiotherapy downstaged the tumor. However, the risk for postoperative mortality was higher in the chemoradiotherapy plus surgery group (odds ratio 2.10). Dr Fiorica and colleagues concluded, In patients with resectable esophageal cancer, chemoradiotherapy plus surgery significantly reduces 3 year mortality compared with surgery alone . However, postoperative mortality was significantly increased by neoadjuvant chemoradiotherapy . Further large scale multicenter randomized controlled trials may prove useful to substantiate the benefit on overall survival . ...
Our study showed that obesity is a critical prognostic factor for LC in rectal cancer. The strategy of improving LC in these patients could bring about a better outcome.. Obesity affects not only surgical complications but also treatment outcomes in rectal cancer patients [19]. Clark et al. [20] reported that elevated visceral adiposity was associated with an increased risk of recurrence after neoadjuvant chemoradiation in rectal cancer. Our results bolster this view. For local treatment, sufficient resection of the tumor might be difficult in obese patients because of limited surgical visibility. In addition, increased set-up uncertainty during RT in obese patients might influence the treatment results. Personalized RT may improve the LC rate in obese patients. An increase in the boost dose of RT in obese rectal cancer patients should be considered to reduce local failure. Intensive systemic treatment and active secondary prevention can also reduce the risk of local recurrence in obese ...
The prognosis of esophageal cancer is poor as most patients present with locally advanced or metastatic disease. The treatment of choice in patients with locally advanced disease (T2-4a/N1-3/M0) is radical surgery with neoadjuvant chemoradiation. Nevertheless, even after neoadjuvant chemoradiation, recurrences occur frequently and complete responses are still relatively low. The response rate of neoadjuvant treatment (41.4 Gy with concurrent carboplatin/paclitaxel) varies between 22%-35%. Another problem is the high rate of recurrences (up to 50%), even after a pathologic complete response (pCR). To gain more insight in the cause of the relatively low response rate and recurrences after pCR, we need to obtain a better understanding of the nature of these tumors and determine better predictive factors. A population of cells the so-called cancer stem-like cells (CSCs) is known to be highly resistant to chemoradiation and therefore targeting these cells might contribute to a better response. With ...
BACKGROUND We systematically reviewed and performed a meta-analysis of the available data regarding neoadjuvant chemo- and/or radiotherapy with special emphasis on tumor response/progression rates, toxicities, and clinical benefit, i.e. resection probabilities and survival estimates. METHODS AND FINDINGS Trials were identified by searching PUBMED, MEDLINE, and the Cochrane Central Register of Controlled Trials from 1966 to Feb 2015. A total of 18 studies (n = 959) were analyzed. the estimated fraction of patients with complete response was 2.8% (CI 0.8-4.7%) and with partial response 28.7% (CI 18.9%-38.5%). Stable disease was averaged to 45.9% (CI 32.9%-58.9%) in all patients and tumor progression under therapy occurred by estimation in 16.9% (CI 10.2%-23.6%) of the patients. The weighted frequency of those who underwent resection was 65.3% (CI 54.2%-76.5%), and the proportion of R0 resection amounted to 57.4% (CI 48.2%-66.5%). The weighted mean of median survival amounted to 17.9 months (range: 14.7
BACKGROUND: The aim of the study was to evaluate the added value of the apparent diffusion coefficient (ADC) of diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with rectal cancer who received neoadjuvant chemoradiotherapy (CRT). The use of DW-MRI for response evaluation in rectal cancer still remains a widely investigated issue, as the accurate detection of pathologic complete response (pCR) is critical in making therapeutic decisions. PATIENTS AND METHODS: Thirty-three patients with locally advanced rectal cancer were evaluated retrospectively by MRI in addition to diffusion-weighted images (DWI) and its ADC pre- and post-neoadjuvant CRT ...
Fingerprint Dive into the research topics of Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Together they form a unique fingerprint. ...
Neoadjuvant chemoradiotherapy did not improve resection rates or survival outcomes in patients with early-stage, locally advanced esophageal cancer.
B71 Background: In locally advanced stages of rectal cancer preoperative combined modality treatment has become the standard therapeutical intervention. Efficacy of neoadjuvant chemoradiation is compromised in some patients by so far unknown factors. These patients could be saved from side effects and surgery could be scheduled without delay. The aim of the present study was to investigate topoisomerase I expression as a potential parameter for predicting tumor response to irinotecan in comparison to adjacent normal tissue.Methods: Twenty patients with rectal cancer clinical stages T3/4 Nx or N+ were recruited to receive weekly neoadjuvant irinotecan (1 hour before radiation) and capecitabine as well as cetuximab with a concurrent RT dose of 50.4 Gy (45+5.4 Gy).Surgery was scheduled 4-6 weeks after the completion of chemoradiation.Samples of normal and tumor tissues of all patients were collected before neoadjuvant treatment. Initially, RNA-oligonucleotid-array of six patients (three ...
CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study
An Absolute Standardized Uptake Value Is More Useful than the Decreased Rate of Uptake of FDG-PET to Predict Responses to Neoadjuvant Chemoradiotherapy for Esophageal Cancer. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
A summary of using the maximum entropy principle from information theory to reconstruct a PDF (or other distributions) given a finite number of moments. This is quite useful especially when using the method of moments in population balances or related stochastic transport processes. The document also includes some results from my code for reconstructing some bimodal and trimodal Gaussian distributions, beta, and log-normal distributions. ...
"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial". The Lancet. 358 ( ...
Adjuvant therapy followed by liver transplantation may have a role in treatment of certain unresectable cases. Locoregional ... The role of combined chemoradiotherapy in this setting is unclear. However, if the tumor tissue margins are positive, ... If the tissue margins are negative (i.e. the tumor has been totally excised), adjuvant therapy is of uncertain benefit. Both ... 2012). "Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review ...
... showed prognostic superiority of adjuvant chemotherapy over chemoradiotherapy. The European Society for Medical Oncology ... Clinical trials are often conducted for novel adjuvant therapies. The role of radiotherapy as an auxiliary (adjuvant) treatment ... After surgery, adjuvant chemotherapy with gemcitabine or 5-FU can be offered if the person is sufficiently fit, after a ... However, there is a continuing tendency for clinicians in the US to be more ready to use adjuvant radiotherapy than those in ...
... surgery with adjuvant chemoradiotherapy. The chemotherapy drugs paclitaxel and carboplatin have shown a clinical (but not ... No link has been found between malignancy and initial chemoradiotherapy treatment, and the overall survival rate was very poor ... HPS stain Craniopharyngiomas are usually successfully managed with a combination of adjuvant chemotherapy and neurosurgery. ...
... 19 (2007 -2012, 619 pts) - Randomized study of Zalutumumab (anti-EGFr) as adjuvant to radiotherapy. ClinicalTrials.gov ... Registration study of chemoradiotherapy in NPC DAHANCA 15 (2003-2004, 28 pts) - Phase I-II study of Zalutumumab (anti-EGFr) as ... A randomized non-inferiority trial of hypoxia-profile guided hypoxic modification with nimorazole during radiotherapy/chemo-radiotherapy ... A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer ...
Cancer treatment now is focused on limited surgery and adjuvant chemoradiotherapy rather than radical surgery, and medical ...
MacDonald (6 September 2001). "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or ... Sakuramoto (1 November 2007). "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine". NEJM. 357 (18): ...
Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with ... with and following concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in women with locally advanced ... "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after ...
In August 2021, the U.S. FDA approved nivolumab for the adjuvant treatment of people with urothelial carcinoma (UC) who are at ... cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy. ... Nivolumab is indicated for the adjuvant treatment of people with melanoma with involvement of lymph nodes or in people with ... On 20 December 2017, the FDA granted approval to nivolumab for adjuvant treatment of melanoma with involvement of lymph nodes ...
... alone or chemoradiotherapy (CRT), which hampered the comparison of the efficacy of RT alone with that of surgery combined with ... adjuvant RT. But some effort had been made to reflect the role of surgery in salivary gland tumours. Treatment may include the ...
In elderly people with newly diagnosed glioblastoma who are reasonably fit, concurrent and adjuvant chemoradiotherapy gives the ... Mason WP, Mirimanoff RO, Stupp R (2006). Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for ... December 2008). "Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of ... "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a ...
... adjuvant chemoradiotherapy is critical in the case of a completely removed tumor, as with no other therapy, recurrence occurs ... Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition ... Analgesic adjuvant Chemotherapy, +Adjuvant at the US National Library of Medicine Medical Subject Headings (MeSH) Anampa, Jesus ... As a result of complications that can stem from liberal use of adjuvant therapy, the philosophy surrounding the use of adjuvant ...
Evidence suggests chemoradiotherapy may increase overall survival and reduce the risk of disease recurrence compared to ... Falcetta FS, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT, Rosa DD (November 2016). "Adjuvant platinum-based chemotherapy ... Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC) (January 2010). "Reducing uncertainties about the ... Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B (December 2014). "Adjuvant ...
Higher tumour grades may benefit from adjuvant treatment such as platinum-based chemotherapy. Optimal debulking is used to ... This combination approach may be substituted with chemoradiotherapy alone in some. Hysterectomy and bilateral oophorectomy is ... If nodal disease is confirmed, adjuvant radiotherapy is administered. Treatment depends on the stage of vaginal cancer. ...
March 2013). "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent ... The addition of another modality of treatment is referred to as adjuvant (literally helping) therapy, compared to its use as ... The adequacy of surgical resection is a major factor in determining the role of postoperative adjuvant therapy. In the presence ... Such patient selection may enable them to avoid the morbidity of additional adjuvant treatment. In the absence of favourable ...
"Adjuvant docetaxel/Cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study". Critical ... "Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer with High-Dose Radiation and Oxaliplatin-Containing ... "Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study". Critical ...
Moreover, no patient in the trial needed chemoradiotherapy or surgery, and no patient reported adverse events of grade 3 or ... For people who have undergone curative surgery or adjuvant therapy (or both) to treat non-metastatic colorectal cancer, intense ... For locally advanced rectal cancer, neoadjuvant chemoradiotherapy has become the standard treatment. Additionally, when surgery ... 2016). "A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer". International Journal of Biological ...
"Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial". ... relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy". Clinical Cancer ...
... incomplete Freund's adjuvant - indinavir - indium In 111 ibritumomab tiuxetan - indium In 111 pentetreotide - indole-3-carbinol ... chemoradiotherapy - chemosensitivity - chemosensitivity assay - chemosensitizer - chemotherapeutic agent - chemotherapy - ... uvula vaccine adjuvant - vaccine therapy - vaccinia CEA vaccine - vaginal cancer - vaginal melanoma-vaginal tumors - ... adjuvant therapy - adrenocortical - Adriamycin - adult T-cell leukemia/lymphoma - AE-941 - AEE788 - aerobic metabolism - ...
May 2009). "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in ... December 2008). "Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas". Journal of ...
In locally advanced adenocarcinoma of middle and lower rectum, regional hyperthermia added to chemoradiotherapy achieved good ... Hyperthermia is usually applied as an adjuvant to radiotherapy or chemotherapy, to which it works as a sensitizer, in an effort ...
Lecavalier-Barsoum M, Quon H, Abdulkarim B (May 2014). "Adjuvant treatment of anaplastic oligodendrogliomas and ... surgical resection while glioblastoma multiforme has a median survival of only 12 months even with aggressive chemoradiotherapy ...
"Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer". The Cochrane Database of ... as would be expected with the concurrent chemoradiotherapy, which is the current gold standard treatment for advanced head and ... interpretation is difficult since cetuximab-radiotherapy was not directly compared to chemoradiotherapy. The results of ongoing ...
The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy. Sella Tal ... Clinical Utility of Circulating Tumor Cells for Predicting Major Histopathological Response after Neoadjuvant Chemoradiotherapy ... Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III ...
Chen et al of 4815 patients with MCC of the head and neck indicated that postoperative adjuvant therapy with chemoradiotherapy ... The role of adjuvant therapy in the management of head and neck merkel cell carcinoma: an analysis of 4815 patients. JAMA ... Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol. 2006 Jun. 142(6):693-700. [QxMD MEDLINE Link]. ... Adjuvant chemotherapy is generally used postoperatively, especially when wide surgical margins are unattainable or when the ...
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. Brooks Gabriel A ... Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal ... The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK- ... between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine ...
A study by Mattos et al indicated that chemoradiotherapy in children with head and neck rhabdomyosarcoma can significantly ... Patients received multimodal treatment, including polychemotherapy (all patients), adjuvant radiation therapy (24 patients), ...
Guideline] Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small Cell Lung Cancer. ... Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16. 377 (20):1919-1929. [ ... Outcomes After Adjuvant Platinum-based Chemotherapy in Elderly NSCLC Patients with T4 Disease. Ann Surg Oncol. 2012 Nov 1. [ ... Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node-negative T3 and T4 non-small cell lung cancer. J ...
Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials ... Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced ... Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal ... Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: ...
Neo-adjuvant chemotherapy with cisplatin and short infusional 5-FU in advanced head and neck malignancies.. Aich, Ranen Kanti; ... Induction followed with concurrent chemo radiotherapy in advanced head & neck cancer.. Yogi, Veenita; Singh, O P. ...
Adjuvant chemoradiotherapy: Within 16-28 days after the first vaccination, patients receive fluorouracil (5-FU) IV continuously ... PURPOSE: This phase II trial is studying how well giving vaccine therapy together with adjuvant chemoradiotherapy works in ... Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF ... Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma ...
Conclusions: Radical gastrectomy with D2 lymph node dissection and IORT followed by adjuvant chemoradiotherapy appeared to be ... Intraoperative Radiotherapy Combined With Adjuvant Chemoradiotherapy for Locally Advanced Gastric Adenocarcinoma. Authors: Fu, ... Intraoperative Radiotherapy Combined With Adjuvant Chemoradiotherapy for Locally Advanced Gastric Adenocarcinoma. International ... Of the 97 patients, 51 received adjuvant concurrent chemotherapy (5-fluorouracil, leucovorin, docetaxel, and cisplatin) and ...
Dive into the research topics of Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human ... T1 - Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated ... title = "Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated ... Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated ...
Should salvage adjuvant therapy be considered for small cell lung cancer patients after incidental surgical resection? ... while adjuvant chemo-radiotherapy (ad-CRT) was associated with a lower risk of death (HR: 0.279; 95% CI: 0.102-0.761, P=0.013). ... while adjuvant chemo-radiotherapy (ad-CRT) is recommended for N2 patients.[18] According to NCCN guidelines, ad-CRT is ... compared to omission of adjuvant therapy. For pathological N1 or N2 (pN1/2) cases (n=91), taking no adjuvant therapy cases as a ...
Return to Article Details RESECTABILITY RATES IN LOCALLY ADVANCED ESOPHAGEAL CARCINOMA FOLLOWING NEO-ADJUVANT CHEMO- ...
... neo-adjuvant therapy followed by surgery, and definitive chemoradiotherapy (dCRT). However, whether neo-adjuvant therapy or ... neo-adjuvant therapy followed by surgery, and definitive chemoradiotherapy (dCRT). However, whether neo-adjuvant therapy or ... neo-adjuvant therapy followed by surgery, and definitive chemoradiotherapy (dCRT). However, whether neo-adjuvant therapy or ... T1 - Neo-adjuvant therapy or definitive chemoradiotherapy can improve laryngeal preservation rates in patients with cervical ...
keywords = "adjuvant chemoradiotherapy, p-Akt, proximal extrahepatic bile duct cancer",. author = "Kim, {Byoung Hyuck} and ... expressions in patients undergoing adjuvant chemoradiotherapy (CRT) for proximal extrahepatic bile duct (EHBD) cancer. Methods ... expressions in patients undergoing adjuvant chemoradiotherapy (CRT) for proximal extrahepatic bile duct (EHBD) cancer. Methods ... expressions in patients undergoing adjuvant chemoradiotherapy (CRT) for proximal extrahepatic bile duct (EHBD) cancer. Methods ...
The aim of this study was to compare the efficacy of NAC plus IMRT and concurrent chemoradiotherapy (CCRT) plus adjuvant ... and subsequently received adjuvant cisplatin and 5-FU. The survival rates were assessed by Kaplan-Meier analysis, and the ... From: Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant ...
... adjuvant therapies, systemic therapies, and single-agent regimens. Surgical resection Surgery is the only curative modality for ... Adjuvant chemoradiotherapy regimens for stage IB-III:. * 5-FU 225 mg/m2 IV daily during radiation [10] or ... Preoperative chemoradiotherapy in the treatment of gallbladder cancer. Am Surg. 1999 Mar. 65(3):241-6. [QxMD MEDLINE Link]. ... Neoadjuvant chemoradiotherapy is not currently a standard option for patients with biliary tract cancer. In a small selected ...
Timing of the consult (e.g., pre-operative/pre-treatment; immediate postoperative; during recovery; during adjuvant (chemo) ... obtaining a detailed description of the individuals current function and needs, based on the surgical resection or (chemo)radiotherapy ... Functional outcomes and quality of life after chemoradiotherapy: Baseline and 3 and 6 months post-treatment. Dysphagia, 29, 365 ... Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: Use it or lose it. JAMA Otolaryngology-Head ...
The aim of this study was to conduct a critical review of the role of adjuvant therapy in the treatment of craniofacial ... The aim of this study was to conduct a critical review of the role of adjuvant therapy in the treatment of craniofacial ... Method We conducted a critical review of the past and contemporary literature available, focusing on adjuvant oncological ... Better understanding of tumor biology allows the construction of more complex treatment strategies, incorporating adjuvant ...
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers ... Post Surgery all patients will receive additional adjuvant chemotherapy Number of patients enrolled: Screened 350 Enrolled 314 ... Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers (POLCAGB) * ... or concurrent chemo-radiation in this cancer.Use of neoadjuvant treatment with chemotherapy alone or chemoradiotherapy has ...
Adjuvant therapy followed by liver transplantation may have a role in treatment of certain unresectable cases. Locoregional ... The role of combined chemoradiotherapy in this setting is unclear. However, if the tumor tissue margins are positive, ... If the tissue margins are negative (i.e. the tumor has been totally excised), adjuvant therapy is of uncertain benefit. Both ... 2012). "Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review ...
Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck ... Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for ... Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida ... Tanvetyanon T. Adjuvant treatment of breast cancer with exemestane. N Engl J Med. 2004 Jul.351(1):100-102. Pubmedid: 15237463. ...
... in patients who received neoadjuvant capecitabine-based chemoradiotherapy followed by TME and optional adjuvant chemotherapy. [ ... Adjuvant Therapy. Although radical resection of rectum is the mainstay of therapy, surgery alone has a high recurrence rates. ... Adjuvant chemoradiation therapy. Patients with locally advanced rectal cancer (T3-4, N0, M0 or any T, N1-2, M0) should receive ... Adjuvant chemotherapy. Chemotherapy options for rectal cancer have greatly expanded in recent years, but the efficacy of ...
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a ...
If there are poor-risk features, adjuvant concurrent chemoradiotherapy is indicated.. N/A ... Concurrent chemoradiotherapy offers a significantly higher chance of larynx preservation than radiation therapy alone or ... With this last approach, survival is similar to that associated with chemoradiotherapy when timely salvage surgery is ... For patients who desire larynx-preservation therapy but are not candidates for organ-preservation surgery or chemoradiotherapy ...
Control group will receive standard capecitabine based chemoradiotherapy. Patients with mesorectal fascia-positive or ycT4a/b ... All patients will receive 4 cycles of XELOX as adjuvant chemotherapy after TME. ... safety of FOLFOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the efficacy of standard Chemoradiotherapy ... efficacy and safety of mFOLFOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to standard chemoradiotherapy. ...
A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone ... Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer. Eur. J. Gynaecol. Oncol. 35, 393-399 (2014). ... Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342-2350 (2018). ...
Chemotherapy as part of initial potentially curative therapy (given as part of adjuvant or concomitant chemoradiotherapy) that ... NOTE: Chemotherapy as part of initial potentially curative therapy (given as part of adjuvant or concomitant chemoradiotherapy ...
... adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer. ... What does this mean for patients: There are few adjuvant treatment options that are currently used for people with clear cell ... "The study confirms that chemoradiotherapy alone is currently our best possible treatment for women with locally advanced ... What did this study find: Results from the phase 3 OlympiA clinical trial showed that 1 year of adjuvant olaparib (Lynparza) ...
... of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for ...
The completion rates of adjuvant chemotherapy were 76.2% vs. 65.8% (p = 0.305) in each group, respectively. On the whole, the ... 3506 - Short-Term radiotherapy plus chEmotherapy versus Long-term chemoradiotherapy in Locally Advanced Rectal cancer (STELLAR ...
OPDIVO® (nivolumab) is indicated for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or ... junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). ... OPDIVO® (nivolumab), as a single agent, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC ... OPDIVO® (nivolumab) is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal ...
M. Takekuma, Y. Kasamatsu, N. Kado et al., "Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical ... patients received adjuvant radiation therapy, and 3 (4.6%) received adjuvant chemotherapy. In 5 (7.7%) patients, in the period ... four patients with stage IB underwent adjuvant radiation therapy and one patient with stage IA was without adjuvant treatment. ... K. Matsuo, M. Shimada, Y. Aoki et al., "Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer ...
He was treated using definitive concurrent chemoradiotherapy, followed by adjuvant durvalumab. He has remained without evidence ... He was treated using definitive concurrent chemoradiotherapy, followed by adjuvant durvalumab. He has remained without evidence ... He was treated using definitive concurrent chemoradiotherapy, followed by adjuvant durvalumab. He has remained without evidence ... He was treated using definitive concurrent chemoradiotherapy, followed by adjuvant durvalumab. He has remained without evidence ...
Diffusion-weighted MRI has also demonstrated capabilities in the evaluation of tumor response to chemoradiotherapy. To date, ... in the adjuvant setting of operated EC after neoadjuvant chemoradiotherapy [2]. In the metastatic setting, chemotherapy and ... Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus. N. Engl. J. Med. ... Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N. Engl. J. Med. 2021, 384, 1191-1203. [Google ...
  • Gallbladder cancer is not common western world and thus there is lack of evidence regarding the impact of neoadjuvant or concurrent chemo-radiation in this cancer.Use of neoadjuvant treatment with chemotherapy alone or chemoradiotherapy has shown to downsize these tumors to safely undergo R0 resection in few published studies. (centerwatch.com)
  • He was treated using definitive concurrent chemoradiotherapy, followed by adjuvant durvalumab. (jnccn.org)
  • 200 cells/μl) during concurrent chemoradiotherapy (CCRT) is relevant to poor survival. (iiarjournals.org)
  • In this regard, concurrent chemoradiotherapy (CCRT) for cervical cancer as a primary modality might have both a positive effect to sustain circulating lymphocytes by controlling tumor and a negative effect to decrease them by irradiation of peripheral blood vessels included in the pelvic CCRT field. (iiarjournals.org)
  • For unresectable N2 NSCLC concurrent chemoradiotherapy is widely accepted as the standard of care in the context of appropriate physiological reserve. (bmj.com)
  • Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. (e-crt.org)
  • Concurrent chemoradiotherapy (CCRT)±adjuvant chemotherapy is the mainstay treatment. (e-crt.org)
  • Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma(NPC). (inclinicaltrials.com)
  • The results of GP combined with concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma showed 10% of locoregionally advanced NPC patients had complete response after three cycles of GP neoadjuvant chemotherapy, and GP neoadjuvant chemotherapy added to chemoradiotherapy significantly improved recurrence-free survival (85.3% vs 76.5%) and overall survival (94.6% vs 90.3%) among locoregionally advanced NPC patients , as compared with chemoradiotherapy alone. (inclinicaltrials.com)
  • Based on this, this study aims to evaluate the efficacy and safety of gemcitabine plus cisplatin chemotherapy combined with tislelizumab neoadjuvant therapy, followed by cisplatin based concurrent chemoradiotherapy, then followed by tislelizumab adjuvant therapy in the patients with locoregionally advanced nasopharyngeal carcinoma, to provide new evidence for individualized comprehensive treatment in NPC. (inclinicaltrials.com)
  • Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. (ejohg.com)
  • Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. (uchicago.edu)
  • Efficacy and Safety of Concurrent Chemoradiotherapy of Paclitaxel and Carboplatin as Adjuvant Therapy after Primary Surgery in High-risk Cervical Cancer. (ogscience.org)
  • Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. (srobf.cz)
  • Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. (srobf.cz)
  • PURPOSE: In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma. (duke.edu)
  • Prospective Trial of Concurrent Chemoradiotherapy with Protracted Infusion of 5-Fluorouracil and Cisplatin for T4 Esophageal Cancer With or Without Fistula. (kyoto-u.ac.jp)
  • This study includes patients treated with sequential or concurrent chemoradiotherapy, reflective of current U.S. medical practice. (eqrx.com)
  • After incidental resection, adjuvant salvage therapy is widely offered, but the evidence supporting its use is limited. (medscape.com)
  • Patients who incidentally receive surgical resection and are diagnosed with limited disease SCLC after resection should be offered adjuvant therapy as a salvage treatment. (medscape.com)
  • According to ESMO guidelines, adjuvant chemotherapy (ad-chemo) is recommended for pT1-2N1 patients who receive complete surgical resection (R0), while adjuvant chemo-radiotherapy (ad-CRT) is recommended for N2 patients. (medscape.com)
  • Background: Various options are available to treat cervical esophageal cancer (CEC), including primary resection, neo-adjuvant therapy followed by surgery, and definitive chemoradiotherapy (dCRT). (elsevier.com)
  • Spanish Society of Medical Oncology (SEOM) guidelines recommend that all patients who have undergone curative resection of biliary tract cancer receive adjuvant therapy with capecitabine for 6 months. (medscape.com)
  • Methods: Sixty-three patients with proximal EHBD cancer who underwent curative resection followed by adjuvant CRT were enrolled into this study. (ewha.ac.kr)
  • Conclusion: p-Akt expression tended to be associated with a favorable prognosis in patients undergoing curative resection followed by adjuvant CRT for proximal EHBD cancer. (ewha.ac.kr)
  • Tumors originating from the craniofacial region usually present in a locally advanced stage with frequent involvement of adjacent sites and have a strong tendency for local recurrence in the absence of adjuvant therapy, even when the original surgical resection was presumed to be radical. (frontiersin.org)
  • In addition, there is a strong tendency for local recurrence in the absence of adjuvant therapy, even when the original surgical resection was presumed to be radical. (frontiersin.org)
  • Abdelghany K, Robinson LA, Tanvetyanon T. Impact of Robotic-Assisted Thoracic Surgery on the Completion of Adjuvant Chemotherapy Following Lung Cancer Resection. (moffitt.org)
  • The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer. (wjgnet.com)
  • Therefore, NCCN guidelines and ESMO guidelines recommend neoadjuvant chemoradiotherapy (nCRT) combined with total mesorectal resection (TME) as the standard treatment mode for advanced rectal cancer, rather than prophylactic LPND alone [ 7 ]. (biomedcentral.com)
  • Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. (ejohg.com)
  • A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. (ejohg.com)
  • Patients with pT2 disease or R1 resection after curative surgery for gallbladder cancer may benefit from adjuvant radiotherapy. (e-roj.org)
  • Extended cholecystectomy includes cholecystectomy, en bloc hepatic resection, and lymphadenectomy with or without bile duct excision. (e-roj.org)
  • A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. (srobf.cz)
  • Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. (snfge.org)
  • GDC-0084 is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor, which readily crosses the blood-brain barrier and exhibited dose-dependent reductions in tumour growth in Phase I. The Phase II trial is likely to test GDC-0084 as first-line maintenance chemotherapy in newly diagnosed GBM following surgical resection and six weeks of chemoradiotherapy. (edisongroup.com)
  • Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. (nih.gov)
  • Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal. (oncotarget.com)
  • To investigate predictive value of APAF-1 and COX-2 expression in pathologic complete response (pCR) for patients with rectal adenocarcinoma (RAC) who were treated with neoadjuvant chemoradiotherapy (neo-CRT) followed by total mesorectal excision (TME). (oncotarget.com)
  • Neoadjuvant chemoradiotherapy (neo-CRT) followed by total mesorectal excision (TME) is the standard of treatment for patients with locally advanced rectal adenocarcinoma. (oncotarget.com)
  • The effect of adjuvant chemotherapy (AC) following CRT on survival in rectal cancer remains unclear. (whiterose.ac.uk)
  • The most useful QMs identified were 1) the percentage of patients with AJCC Stage III colon cancer who received postoperative CT and 2) the percentage of patients with Stage II or III rectal cancer who received chemoradiotherapy. (va.gov)
  • New National trial: "Watch and Wait" in patients with complete clinical response (CCR) after neo-adjuvant chemoradiotherapy for primary locally advanced rectal cancer. (eu.com)
  • Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. (cdc.gov)
  • Background & Objective: Currently, neoadjuvant chemoradiotherapy, followed by surgery, is the standard treatment for locally advanced rectal cancer. (iranpath.org)
  • Mortality was not reported.Conclusion: Induction chemotherapy, followed by neoadjuvant chemoradiotherapy and surgery, would be an effective and safe modality in locally advanced rectal cancer. (iranpath.org)
  • Postoperative pathologic stage is one of the most important prognostic factors in patients with rectal cancer after surgery and preoperative chemoradiotherapy (CRT). (2minutemedicine.com)
  • Adjuvant chemotherapy is also recommended after surgery for patients with postoperative pathologic stages II and III rectal cancer. (2minutemedicine.com)
  • In this multicenter, randomized, controlled trial, 321 patients with postoperative ypStage II (ypT3-4N0) or III (ypT any N1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and total mesorectal excision (TME) were randomized to receive adjuvant chemotherapy with either fluorouracil and leucovorin (FL) or FOLFOX (oxaliplatin, leucovorin, and fluorouracil) to study disease-free survival (DFS). (2minutemedicine.com)
  • Overall, this study suggests that adjuvant FOLFOX may improve disease-free survival in patients with postoperative ypStage II or III rectal cancer who received preoperative CRT and TME, but is associated with a higher rate of adverse events. (2minutemedicine.com)
  • Health-related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R-04. (mysciencework.com)
  • BackgroundThere has been limited evaluation of health-related quality of life (HRQOL) in rectal cancer patients receiving neoadjuvant chemoradiotherapy. (mysciencework.com)
  • Among academic radiation oncologists, medical oncologists, and colorectal surgeons, the traditional regimen of long-course chemoradiation, surgery, and adjuvant chemotherapy is now infrequently recommended for locally advanced rectal cancer. (clinical-colorectal-cancer.com)
  • To assess prognostic benefits of intraoperative electron beam rays therapy (IOERT) in sufferers with nonmetastatic locally advanced pancreatic cancers (LAPC) and evaluate optimal adjuvant treatment after IOERT. (rawveronica.com)
  • Adding the PD-L1 monoclonal antibody avelumab (Bavencio) to standard-of-care chemoradiotherapy for unresected, locally advanced squamous cell carcinoma of the head and neck (HNSCC) failed to prolong the primary end point of progression-free survival (PFS). (targetedonc.com)
  • A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma. (amedeo.com)
  • Background: The most accepted treatment for locally advanced pancreatic cancer is chemoradiotherapy. (elsevier.com)
  • Methods: From June 1999 to December 2003, 28 patients with locally advanced pancreatic cancer (group 1) were enrolled for institutional trials of gemcitabine-based chemoradiotherapy. (elsevier.com)
  • Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. (hemonc.org)
  • Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. (srobf.cz)
  • The first of two Phase III clinical trials, the international, randomized, double-blind, placebo-controlled TrilynX study (NCT04459715) to evaluate the efficacy and safety of xevinapant versus placebo when added to definitive chemoradiotherapy (CRT) in patients with unresected locally advanced (LA) SCCHN, is currently recruiting. (emdserono.com)
  • Fifty six year old lady a case of squamous cell carcinoma of the mid thoracic esophagus underwent thoraco-laparoscopic esophagectomy in prone position following completion of neo-adjuvant chemo-radiotherapy. (sages.org)
  • Although utilization of adjuvant chemotherapy and chemo-radiotherapy has been investigated more frequently because of the tendency of distant recurrence in UCS, even with early-stage disease (6), the optimal postoperative management is still controversial in the early-stage. (balkanmedicaljournal.org)
  • Determine overall and disease-free survival of patients with resected stage I or II adenocarcinoma of the pancreas treated with adjuvant chemoradiotherapy in combination with GVAX pancreatic cancer vaccine. (clinicaltrials.gov)
  • Mediandisease free survival in the adjuvant chemoradiotherapy group was 22 months versus 14 months inthe neoadjuvant/perioperative cohort. (who.int)
  • Patients receiving adjuvant chemotherapyafter surgery had median overall survival of 39 months versus 26 months in the neoadjuvant arm{p=.039, Wilcoxon Gehan statistic}.In our clinical set-up, adjuvant chemoradiotherapy seems to resultin better overall survival and disease free survival in resectable gastro-esophageal junctionadenocarcinoma though we should be cautious in interpreting retrospective and non-randomizeddata. (who.int)
  • however, a later study investigating chemoradiotherapy with 5-FU did not show a survival benefit. (medscape.com)
  • Preoperative chemoradiotherapy (CRT) can cause regression in the severity of EMVI and subsequently improve survival whereas mrEMVI persisting after CRT confers an increased risk of recurrence. (whiterose.ac.uk)
  • Given high survival rates in stage I patients reported in small series with surgery alone, adjuvant chemoradiotherapy (CRT) has traditionally been recommended only for patients with high risk disease. (utmb.edu)
  • As reported in The New England Journal of Medicine by Dean F. Bajorin, MD , of the Department of Medicine, Memorial Sloan Kettering Cancer Center, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo. (ascopost.com)
  • Is Disease-Free Survival the Best Endpoint for Adjuvant Nivolumab in High-Risk, Muscle-Invasive Urothelial Carcinoma? (ascopost.com)
  • Pembrolizumab given as a lead-in dose, concomitantly with chemoradiotherapy and then adjuvantly for one year failed to deliver a statistically significant improvement in event-free survival as a primary endpoint when compared with placebo. (ecancer.org)
  • It was also shown that survival improved for patients with oesophageal cancer the last 26 years, probably due to the introduction of neoadjuvant chemoradiotherapy and centralisation of surgery. (eur.nl)
  • So we hypothesize that GP neoadjuvant chemotherapy combined with tislelizumab and tislelizumab adjuvant therapy could further improve survival of patients with locaregionally advanced NPC. (inclinicaltrials.com)
  • After success in safe surgery for esophageal cancer, improvement of survival was attempted with an extended radical lymphadenectomy or by adjuvant chemo-radiotherapies combined with an operation. (kms-igakkai.com)
  • Various adjuvant therapies have been also developed, and the survival has gradually improved. (kms-igakkai.com)
  • Many studies have investigated whether adjuvant radiotherapy and/or chemotherapy lower recurrence rates and ultimately improve survival [ 9 - 16 ]. (e-roj.org)
  • Some, but not all, retrospective studies show a survival benefit with adjuvant radiotherapy or chemoradiotherapy. (e-roj.org)
  • Comment on: The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-Negative Esophageal Adenocarcinoma. (amedeo.com)
  • There was no statistical significance for disease-free survival between observation and receiving any type of adjuvant therapy following staging surgery. (balkanmedicaljournal.org)
  • Performing any adjuvant therapy following comprehensive lymphadenectomy was not related to the improved survival of the stage I disease. (balkanmedicaljournal.org)
  • Adjuvant radiotherapy likely improves local control but has no significant effect on survival of early-stage UCS (11,12). (balkanmedicaljournal.org)
  • And, although only adjuvant fluoropyrimidines have demonstrated a survival benefit, oxaliplatin-based regimens are widely used in this setting based on the extrapolation of results from patients with colon cancer. (2minutemedicine.com)
  • Perioperative outcome and survival of group 1 were compared with 44 patients primary resected for localized cancer with or without adjuvant treatment in the same time period (group 2). (elsevier.com)
  • Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. (plex.page)
  • Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. (uchicago.edu)
  • Furthermore, the synopsis of the overall survival results of neoadjuvant trials suggests a higher rate compared to adjuvant trials. (biomedcentral.com)
  • For all stages, 5 year overall survival rate is 6% form en and 3% for women[ 1 ]. (biomedcentral.com)
  • This SMAD4 survival benefit persisted after adjustment for prognostic factors including tumor size, margin status, lymph node status, pathological stage, blood loss, and use of adjuvant chemoradiotherapy. (biosb.com)
  • Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center. (openrepository.com)
  • Moreover deviations from protocol specified RT suggestions are recognized to take place in cooperative group studies during process administration (10 11 Because deviations from set up QA guidelines have been shown to effect on survival in several non-oncologic scientific contexts (12-15) and due to the prevailing controversy about the function of RT in the adjuvant administration of pancreatic adenocarcinoma the next secondary evaluation of RTOG 9704 was performed. (themodernsolution.com)
  • Better understanding of tumor biology allows the construction of more complex treatment strategies, incorporating adjuvant chemotherapy either pre- or postoperatively. (frontiersin.org)
  • After surgery, a final biopsy is performed, and adjuvant radiation is advised to patients who exhibit positive margins of residual tumors, multiple lymph node involvements, or other high-risk features. (onco.com)
  • Nonmetastatic LAPC sufferers with smaller sized size tumors could obtain positive long-term success outcomes with cure strategy incorporating IOERT and postoperative adjuvant treatment. (rawveronica.com)
  • 2008 CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). (prelekara.sk)
  • In 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). (jto.org)
  • In stage III NSCLC, patients with no tumour progression following combination chemoradiotherapy have better OS with maintenance durvalumab. (iaslc.org)
  • Two populations will be included: participants with resected Stage IIB-IIIB (early-stage) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. (genentech-clinicaltrials.com)
  • A clinical trial with aumolertinib in adjuvant EGFR-mutated NSCLC is ongoing in China with plans to expand the study into a multiregional clinical trial. (eqrx.com)
  • A promising adjuvant in cisplatin based chemoradiotherapy by cellular redox management[J]. Food and Chemical Toxicology, 2013, 59:715-723. (cnif.cn)
  • Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. (hemonc.org)
  • A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). (srobf.cz)
  • Here, we report prespecified and exploratory analyses of adjuvant chemotherapy use and outcomes from ADAURA. (jto.org)
  • Meta-analysis revealed similar clinical outcomes using up-front chemoradiotherapy followed by chemotherapy versus chemotherapy alone in LAPC [ 6 ]. (e-crt.org)
  • HRQOL outcomes in the National Surgical Adjuvant Breast and Bowel Project R-04 trial are examined in this article.MethodsBetween 2004 and 2010, R-04 patients were invited to enroll in the HRQOL sub. (mysciencework.com)
  • We aimed to conduct the retrospective analysis of resectable Gastro-esophageal junctionadenocarcinomas treated at our facility with either adjuvant chemoradiotherapy (ACT) or neoadjuvant/perioperative chemotherapy (NACT) and investigate their impact on the clinical outcome.A total of79 patients of Gastro -esophageal junction adenocarcinomas completed treatment with curative intentbetween January, 2010 and December 2016 and were included in the analysis. (who.int)
  • The aim of this study was to conduct a critical review of the role of adjuvant therapy in the treatment of craniofacial malignancy. (frontiersin.org)
  • However, novel surgical procedures and adjuvant modalities have made treatment feasible for malignancies previously considered impossible ( 1 ). (frontiersin.org)
  • This study aims to provide a critical review of the role of adjuvant therapy in the treatment of craniofacial malignancy. (frontiersin.org)
  • The role of adjuvant treatment for invasive, high-grade bladder cancer remains controversial and challenging. (ascopost.com)
  • On May 20, 2021 , nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease after neoadjuvant chemoradiotherapy. (ascopost.com)
  • For description of chemotherapy and chemoradiotherapy regimens, see Gastric Cancer Treatment Protocols . (medscape.com)
  • [4] Adjuvant treatment such as chemoradiotherapy or radiotherapy is favored for distant extracranial metastases. (researchsquare.com)
  • [10, 11] Lacking an accurate diagnosis, pediatric patients with IESL may receive unnecessary invasive investigation and adjuvant treatment. (researchsquare.com)
  • 5293 - Factors predicting adherence to a tailored-dose adjuvant treatment based on geriatric assessment in elderly people with colorectal cancer: a prospective study. (esmo.org)
  • This experimental neoadjuvant schedule should be delivered only within clinical trials, the standard preoperative treatment remaining chemoradiotherapy. (jle.com)
  • An approach of induction treatment followed by surgery and surgery followed by adjuvant treatment both appear justified, though there is evidence suggesting higher treatment completion rates with an induction approach. (bmj.com)
  • When definitive chemoradiotherapy is the preferred treatment option this should be delivered concurrently in the context of adequate physiological reserve. (bmj.com)
  • Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. (lookformedical.com)
  • Nevertheless, many gastric cancer patients that are eligible for perioperative treatment do not receive the adjuvant component of perioperative treatment or they do not receive chemotherapy at all in addition to surgery. (eur.nl)
  • In addition, previous studeis showed that PD-1 antibody adjuvant therapy had good feasibility and effectiveness in the treatment of nasopharyngeal carcinoma. (inclinicaltrials.com)
  • The role of radiotherapy in the adjuvant treatment of gastric cancer (GC) remains to be elucidated. (ejohg.com)
  • This study aimed to assess the additional benefit of radiotherapy in the adjuvant treatment of GC. (ejohg.com)
  • In this study, 11 of 28 patients received radical surgery, and the rest received non-surgery treatment (chemoradiotherapy or radiotherapy alone). (alliedacademies.org)
  • The effect of adjuvant treatment has not been clearly demonstrated due to the rarity of gallbladder cancer and the lack of randomized trials. (e-roj.org)
  • Chemoradiotherapy followed by chemotherapy might be a recommended adjuvant treatment strategy for well-selected instances. (rawveronica.com)
  • No significant difference in total remission of abdominal/back pain was recognized among 5 adjuvant treatment organizations (data are not demonstrated). (rawveronica.com)
  • Adjuvant delivery of immune checkpoint inhibitors can also allow for patient selection according to treatment response, a strategy that has been successful in esophageal cancers. (targetedonc.com)
  • Two patients (6.9%) did not complete adjuvant treatment. (iranpath.org)
  • For patients in whom the disease is considered technically resectable, the main treatment options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy (CRT)) or CRT followed by adjuvant immunotherapy (dependent on programmed death ligand 1 status). (ersjournals.com)
  • The two main multimodal treatment options in this setting are chemoradiotherapy (CRT) (with or without adjuvant immunotherapy) or surgery (with neoadjuvant or adjuvant chemotherapy (Ch)/neoadjuvant CRT). (ersjournals.com)
  • With gemcitabine becoming the preferred treatment strategy for advanced pancreatic cancer [ 3 ], clinical trials comparing chemoradiotherapy with gemcitabine alone in LAPC patients showed mixed results [ 4 , 5 ]. (e-crt.org)
  • The treatment groups were surgery alone, radiotherapy (55·8 Gy), chemoradiotherapy (chemotherapy and 55·8 Gy radiotherapy), and neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost based on margins with continued chemotherapy). (elsevier.com)
  • Most low-risk patients can be cured without adjuvant therapy, thereby avoiding known long-term treatment complications. (elsevier.com)
  • The most common treatment for locally diagnosed esophageal squamous cell carcinoma patients is Neoadjuvant chemoradiotherapy followed by surgery. (plex.page)
  • At a press conference at ASCO 2014, Dr Perez presents the findings from a large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), which suggest that post-surgery (adjuvant) treatment using a combination of two HER2-targeted drugs - trastuzumab and lapatinib - is no more effective than standard treatment with trastuzumab alone for women with early HER2-positive breast cancer. (ecancer.org)
  • A Phase II Study of Neoadjuvant and Adjuvant Chemotherapy with 5-Fluorodeoxyuridine, Leucovorin, Oxaliplatin and Docetaxel in the Treatment of Previously Untreated Advanced Esophageal Adenocarcinoma. (llu.edu)
  • Participants who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy cycle. (genentech-clinicaltrials.com)
  • Treatment Patients had been randomly designated to pre and post chemoradiotherapy (CRT) 5-FU (arm 1) or gemcitabine (arm 2). (themodernsolution.com)
  • A comprehensive histopathology report of colorectal carcinoma surgery is important in cancer staging and planning adjuvant treatment. (indianjcancer.com)
  • The development of induction chemotherapy (ICT) followed sequentially by consolidation chemoradiotherapy (CCRT) was based on the rationale of sparing patients with rapidly progressive disease from radical local radiotherapy. (e-crt.org)
  • Gondi V, Bentzen SM, Sklenar KL, Dunn EF, Petereit DG, Tannehill SP, Straub M and Bradley KA: Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. (brazilianjournals.com)
  • Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. (cdc.gov)
  • Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. (ejohg.com)
  • Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. (ejohg.com)
  • Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. (ejohg.com)
  • The subject-matter is illustrated at near a eleemosynary bevy of selected images, highlighting tone findingsHelicobacter pylori Infection and Gastric Cancer -- Is Eradication Enough to Taboo Gastric Cancer 9 The using software is trial renderingAfter adjuvant group therapy, the Emanation Therapy Oncology Place (RTOG) has defined in a consensus panel guidelines as a replacement for the delineation of the clinical aim size (CTV) in pancreatic head cancer (Goodman et al. (janmille.ru)
  • Abstract Purpose To determine the indications for adjuvant chemotherapy (AC) in patients with stage IIa gastric cancer (T3N0M0 and T1N2M0) according to the 7 th American Joint Committee on Cancer (AJCC) Methods A total of 1593 patients with T3N0M0 or T1N2M0 stage gastric cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database for the period 1988.1-2012.12. (researchsquare.com)
  • In most western countries, adjuvant chemotherapy (AC) is suggested in gastric cancer patients whose stage is higher than Ib[2, 3], but in eastern countries, AC is not recommended in T3N0M0 and T1N2M0 (IIa stage) gastric cancer patients[4]. (researchsquare.com)
  • The aim of this study is to evaluate the tolerability and toxicity of adjuvant chemoradiotherapy (CRT) and to analyze the prognosis in patients with operable gastric cancer. (gazi.edu.tr)
  • Should Chemoradiotherapy be used in Node-negative Esophageal or Gastric Adenocarcinoma? (llu.edu)
  • MacDonald et al (4) have reported that in INT 0116 an adjuvant trial for resected gastric adenocarcinoma initially submitted RT fields were judged inappropriate because of inadequate coverage of at risk areas Sitaxsentan sodium for sub-clinical tumor or because of Sitaxsentan sodium unacceptable toxicity risk in 35% of patients. (themodernsolution.com)
  • I give 2 cycles of carboplatin plus paclitaxel before chemoradiotherapy. (targetedonc.com)
  • Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. (uchicago.edu)
  • An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. (amedeo.com)
  • Our findings on regional recurrence may help physicians construct a target volume for adjuvant radiotherapy. (e-roj.org)
  • Adjuvant chemoradiotherapy (CRT) has been shown to reduce the risk of recurrence for patients with risk factors after radi. (cn1699.cn)
  • Metastatic recurrence is more common in those who have residual illness after neo-adjuvant chemotherapy (NAC). (goldendayshealth.com)
  • It may likewise involve Postoperative therapy, that includes adjuvant therapy. (twc-online.com)
  • Chemoradiotherapy did not increase the operative risk, but the interventions were more technically demanding and required a longer postoperative stay. (elsevier.com)
  • These data provide a rationale for prospective clinical trials testing the efficacy of anti-inflammatory or immune-modulating agents as "adjuvant" therapy after lung metastasectomy, in patients with elevated pre- and/or postoperative CRP levels. (springer.com)
  • The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. (roa-ne.com)
  • Post chemoradiotherapy vaccination: Within 4-8 weeks after the completion of chemoradiotherapy, patients receive GVAX pancreatic cancer vaccine ID on days 0, 28, 56, and 196. (clinicaltrials.gov)
  • The protocol of the study is presented in condensed form after an introducing survey on adjuvant and neoadjuvant therapy in pancreatic cancer. (biomedcentral.com)
  • Keywords: Radiotherapy quality guarantee pancreatic adenocarcinoma adjuvant therapy chemoradiotherapy Launch Radiotherapy (RT) coupled with chemotherapy and medical procedures is certainly efficacious in the administration of gastrointestinal carcinoma specifically from the rectum and Sitaxsentan sodium abdomen (1- 4). (themodernsolution.com)
  • Nevertheless whether Sitaxsentan sodium an adjuvant paradigm concerning both RT and chemotherapy or chemotherapy by itself represents your best option for sufferers with curatively resected pancreatic adenocarcinoma is usually controversial (5-9). (themodernsolution.com)
  • Patients were classified into different group according to the type of adjuvant therapy they received and stratified by their pathological lymph node status. (medscape.com)
  • However, controversial results exist regarding both the necessity and type of adjuvant therapy in the presence of high quality lymphadenectomy (5,6,9-11). (balkanmedicaljournal.org)
  • Adjuvant Therapy after Neoadjuvant Therapy for Esophageal Cancer: Who Needs It? (amedeo.com)
  • Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? (elsevier.com)
  • Neoadjuvant or adjuvant chemotherapy or radiotherapy therapy is not shown to be beneficial in patients with cholangiocarcinoma. (gastrotraining.com)
  • PURPOSE The purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma could maintain historical rates for disease control while reducing toxicity and preserving swallow function and quality of life (QOL). (elsevier.com)
  • Our results suggest that adjuvant chemotherapy and radiation therapy with the "sandwich" regimen is associated with acceptable toxicity and satisfactory rates of completion of planned therapy. (viamedica.pl)
  • Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open- label, multicentre, randomised, phase 3 trial. (brazilianjournals.com)
  • 10C13] Considering the potential toxicity of high-dose irradiation, we took buy 2719-05-3 IOERT at 10 to 20?Gy combined with adjuvant therapy. (rawveronica.com)
  • PURPOSE: This phase II trial is studying how well giving vaccine therapy together with adjuvant chemoradiotherapy works in treating patients with resected stage I or stage II adenocarcinoma (cancer) of the pancreas. (clinicaltrials.gov)
  • For patients receiving adjuvant chemotherapy, solid-predominant adenocarcinoma was a significant predictor for poor OS (P = .04). (nycu.edu.tw)
  • Solid-predominant adenocarcinoma was also a significant predictor in patients undergoing adjuvant chemotherapy. (nycu.edu.tw)
  • This study sought to identify potential candidates for adjuvant radiotherapy and patterns of regional failure in patients who underwent curative-intent surgery for gallbladder cancer. (e-roj.org)
  • Control group will receive standard capecitabine based chemoradiotherapy. (centerwatch.com)
  • In this study, a neoadjuvant chemotherapy consisting on mFOLFIRINOX during 3 months, followed by a radio-chemotherapy delivering 50 Gy in 25 fractions and capecitabine as radiosensitiser, compared to an upfront radiochemotherapy followed after surgery by adjuvant chemotherapy. (jle.com)
  • Then, neoadjuvant chemoradiotherapy (radiotherapy 50.4 Gy/28 for 5 days a week concomitant with weekly oxaliplatin 50 mg/m2, as well as capecitabine 825 mg/m2/bid on the days of radiotherapy) was administered. (iranpath.org)
  • The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients. (inclinicaltrials.com)
  • Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. (uchicago.edu)
  • 1818 - Prognostic stratification of pathologic stage in patients with preoperative chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma. (esmo.org)
  • Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. (uchicago.edu)
  • Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. (uchicago.edu)
  • Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. (va.gov)
  • Prognostic stratification of pathologic stage in patients with preoperative chemoradiotherapy followed by curative esophagectomy for localized esop. (esmo.org)
  • Neo-adjuvant therapy or definitive chemoradiotherapy can improve laryngeal preservation rates in patients with cervical esophageal cancer. (elsevier.com)
  • Dive into the research topics of 'Neo-adjuvant therapy or definitive chemoradiotherapy can improve laryngeal preservation rates in patients with cervical esophageal cancer. (elsevier.com)
  • At 2 years, all patients in the neoadjuvant/definitive cohort and 10/13 patients in the adjuvant cohort were still alive. (duke.edu)
  • Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. (clinicaltrials.gov)
  • Adjuvant radiation therapy following mastectomy for breast cancer. (kyoto-u.ac.jp)
  • In some cases, neoadjuvant therapies have actually been presented to improve the efficacy of chemoradiotherapy. (twc-online.com)
  • What is the right adjuvant therapy in colorectal cancer? (jichi.ac.jp)
  • Eortc head and neck surgery and oncology adjuvant chemoradiotherapy in these women. (berea.edu)
  • 950O - Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable lung cancer - the INCREASE trial. (oncoletter.ch)